67 related articles for article (PubMed ID: 9045059)
1. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis].
Milejski P; Orzechowska-Juzwenko K; Pawlik J; Kamienowski J; Horoch E; Niewiński P; Hurkacz M
Neurol Neurochir Pol; 1996; 30(4):571-9. PubMed ID: 9045059
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
[TBL] [Abstract][Full Text] [Related]
3. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
[TBL] [Abstract][Full Text] [Related]
5. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
6. [Oxidation phenotype as a risk factor for development of allergic diseases].
Niewiński P; Orzechowska-Juzwenko K; Patkowski J; Wolańczyk-Medrala A; Nittner-Marszalska M; Rzemisławska Z
Pol Arch Med Wewn; 1999 Jan; 101(1):23-7. PubMed ID: 10592724
[TBL] [Abstract][Full Text] [Related]
7. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
[TBL] [Abstract][Full Text] [Related]
8. Genetically determined sparteine oxidation polymorphism in a Polish population.
Orzechowska-Juzwenko K; Pawlik J; Niewiński P; Milejski P; Dembowski J; Turek J; Goździk A; Swiebodzki L; Hora Z
Eur J Clin Pharmacol; 1994; 46(5):481-3. PubMed ID: 7957549
[TBL] [Abstract][Full Text] [Related]
9. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
[TBL] [Abstract][Full Text] [Related]
10. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
Harmer D; Evans DA; Eze LC; Jolly M; Whibley EJ
J Med Genet; 1986 Apr; 23(2):155-6. PubMed ID: 3712391
[TBL] [Abstract][Full Text] [Related]
12. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
Brøsen K
Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
[TBL] [Abstract][Full Text] [Related]
13. Sparteine oxidation polymorphism in Denmark.
Brøsen K; Otton SV; Gram LF
Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
[TBL] [Abstract][Full Text] [Related]
14. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
[TBL] [Abstract][Full Text] [Related]
15. [Acetylation in disseminated sclerosis and amyotrophic lateral sclerosis].
Zavalishin IA; Kovaleva VL; Larskiĭ EG; Mzhel'skaia TI; Niiazbekova AS
Sov Med; 1986; (9):31-4. PubMed ID: 3798218
[No Abstract] [Full Text] [Related]
16. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
18. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
[TBL] [Abstract][Full Text] [Related]
19. [Occurrence of the fast acetylation phenotype in persons with the radicular syndrome. Preliminary report].
Milejski P; Orzechowska-Juzwenko K; Tota B; Krzysztoń Z
Neurol Neurochir Pol; 1987; 21(6):511-5. PubMed ID: 3449771
[TBL] [Abstract][Full Text] [Related]
20. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
